Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + CCRT in Resectable/Borderline Resectable Pancreatic Cancer
NCT03572400Phase 2Active, not recruiting
- Start
- Nov 2018
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Disease-free survival rate at 2 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03572400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572400.